AZD 9150

Drug Profile

AZD 9150

Alternative Names: AZD9150; IONIS-STAT3-2.5Rx; IONIS-STAT3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3-2.5Rx; ISIS-STAT3Rx; STAT3Rx

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly; Isis Pharmaceuticals
  • Developer AstraZeneca; Ionis Pharmaceuticals; MedImmune; National Cancer Institute (USA)
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Head and neck cancer; Malignant ascites; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Phase I/II Hepatocellular carcinoma; Non-Hodgkin's lymphoma
  • Phase I Diffuse large B cell lymphoma

Most Recent Events

  • 14 Nov 2017 AstraZeneca plans the phase II HUDSON trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA, Austria, Canada, Germany and South Korea, in November 2017 (NCT03334617)
  • 11 Sep 2017 Updated efficacy and adverse events data from the phase Ib/II trial in Head and neck cancer released by Ionis Pharmaceuticals
  • 02 Mar 2017 Phase-II clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02983578)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top